New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 5, 2013
08:13 EDTRHHBY, VRTXVertex flu treatment may become large franchise, says William Blair
After Vertex (VRTX) reported data for its flu treatment, William Blair believes that the data appears promising and superior in some ways to Roche's (RHHBY) Tamiflu, a multibillion dollar franchise. The firm doesn't think the Street has assigned any value to Vertex's flu treatment, and it maintains an Outperform rating on the stock.
News For VRTX;RHHBY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 2, 2015
16:28 EDTVRTXOn The Fly: Top stock stories for Thursday
Subscribe for More Information
14:51 EDTVRTXVertex expects payers to provide 'broad access' for Orkambi
Subscribe for More Information
14:50 EDTVRTXVertex to resume trading at 3:00 PM ET
Subscribe for More Information
14:42 EDTVRTXVertex says 'too early to comment' on international Orkambi pricing
Subscribe for More Information
14:33 EDTVRTXVertex sets Orkambi price at $259,000, sees delivery to pharmacies 'within days'
Following today's confirmation from Vertex that Orkambi has received FDA approval, the company held a conference call providing an update on the drug. Vertex remarked that it is "ready to launch this medicine." Vertex will offer a co-pay assistance program for the drug, with certain eligibility criteria. Company believes it can achieve a similar patient cost situation as Kalydeco. Sets price of Orkambi at $259,000 per year. Expects delivery to pharmacy network "within days."
13:52 EDTVRTXVertex to hold a conference call
Subscribe for More Information
13:47 EDTVRTXVertex confirms FDA approval of ORKAMBI
Vertex Pharmaceuticals announced that the U.S. FDA approved ORKAMBI, the first medicine to treat the underlying cause of cystic fibrosis in people ages 12 and older with two copies of the F508del mutation. It is only indicated for these patients, who can be identified with a genetic test. People with two copies of the F508del mutation represent the largest group of people with CF. Of the 30,000 people in the United States with CF, approximately 8,500 ages 12 and older have two copies of the F508del mutation. ORKAMBI will be available for shipment to specialty pharmacies in the United States within days.
12:47 EDTVRTXVertex to return to profitability with approval, says Piper Jaffray
Subscribe for More Information
12:00 EDTVRTXVertex receives FDA approval for Orkambi
Subscribe for More Information
11:50 EDTVRTXVertex trading halted, pending news
Subscribe for More Information
July 1, 2015
08:46 EDTRHHBYExelixis says FDA extends PDUFA action date for cobimetinib NDA
Subscribe for More Information
June 30, 2015
07:32 EDTVRTXVertex should get Orkambi approval by Monday or sooner, says Piper Jaffray
Subscribe for More Information
05:30 EDTRHHBYGenentech reports ocrelizumab Phase III studies met primary, secondary endpoints
Subscribe for More Information
June 29, 2015
15:28 EDTVRTXVertex management to meet with UBS
Subscribe for More Information
07:47 EDTVRTXCerulean appoints Stuart A. Arbuckle to board of directors, effective June 26
Subscribe for More Information
June 25, 2015
14:03 EDTRHHBYRoche initiated with a Buy at HSBC
Subscribe for More Information
June 24, 2015
09:07 EDTRHHBYCAR-T cancer drug researchers seen as M&A targets, Bloomberg says
Juno Therapeutics (JUNO), Kite Pharma (KITE) and Bluebird Bio (BLUE) are trading well above their IPO levels as takeovers predictions have spurred interest and share increases for the developers of CAR-T gene therapies, said Bloomberg's "Real M&A" column, quoting Dimo Dimov, a professor at the University of Bath’s School of Management, as having said that companies such as Pfizer (PFE), Merck (MRK), Roche (RHHBY) and AstraZeneca (AZN) are "closely watching" the firms. Cellectis (CLLS), which is working with Pfizer on its own approach to CAR-T therapy, has said it wants to bring its therapy to market and doesn’t anticipate a sale, the report noted. Reference Link

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use